Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioOutsource Opens New Facility in Cambridge, Massachusetts

Published: Wednesday, May 01, 2013
Last Updated: Wednesday, May 01, 2013
Bookmark and Share
First North American offices opened in response to surging demand for company’s BioAnalytical and Biosafety services.

BioOutsource Ltd. announced the opening of a new facility in Cambridge, Massachusetts, the company’s first in the United States. The company plans to draw on its unparalleled depth of experience in providing biosimilar characterization assays to its European customers, in providing similar services throughout North America. The announcement was made at the 2013 BIO International Convention, “the Global Event for Biotechnology,” in Chicago, Illinois.

“We have opened this new office, our first in the U.S., in response to  increasing demand from across the North American market for our market-leading BioAnalytical services, and particularly in the field of biological  biosimilar characterization,” commented BioOutsource CEO Gerry MacKay. “Our U.S. office will facilitate engagement with North American customers for our off-the-shelf  biosimilar biological characterization assays, for example for Humira, Enbrel, Rituxan, Herceptin, Remicade, and Avastin.”

The office will be located at the Cambridge Innovation Center, 1 Broadway, 14th Floor, Cambridge, Mass, 02142. The Cambridge Innovation Center is located on Kendall Square, adjacent to the Massachusetts Institute of Technology campus and home to a number of growing life sciences and venture capital firms.

“We are in the fortunate position to have been first-to-market in both Europe and the U.S. with our assays, and count Big Pharma as well as leading biotechnology as valued customers,” said Verna McErlane, PhD, BioOutsource Director of Sales & Business Development, BioAnalytical Division. “We look forward to being able to interact with them and provide our market-leading services, that much more readily, from our North American base of operations in Cambridge. Cambridge is, of course, part of greater Boston, which is now the number one cluster for early-stage biotechnology, and a growing center of operations for some of the world’s leading pharmaceutical firms, as well.” Mr. MacKay concluded, “We see the North American market as an essential strategic element of our global expansion plans. We remain committed to not only growing our business in North America but in nurturing our relationships with our existing North American clients, as well. We invite all our customers and potential customers to stop by our new offices whenever you are in the Boston area.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Angina Drug Could Inform A New Strategy To Fight Cryptococcosis
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!